Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03166800 · ClinicalTrials.gov registry record · Phase 1
MitoQ for Fatigue in Multiple Sclerosis
A Phase 1 study, sponsored by Oregon Health and Science University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT03166800: Clinical Trial Phase 1 study, sponsored by Oregon Health and Science University.
NCT03166800 is a Phase 1 study that was terminated before completion, run by Oregon Health and Science University. The registered enrollment target is 9 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03166800, a Phase 1 study, was terminated before completion, sponsored by Oregon Health and Science University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether MS patients who receive Oral mitoquinone (MitoQ) have less fatigue than those receiving a placebo. A comparison between patient's fatigue scored at baseline and fatigue scored 12 weeks after study drug initiation will assess if MitoQ has a significant change in fatigue.
Primary Outcome
This primary outcome measure will be the difference from baseline in fatigue scores as measured by Modified Fatigue Impact Scale (MFIS) Score at 12 weeks post study drug initiation.
Interventions
- DRUG Placebo
- DRUG Mitoquinone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2018-09-15 |
| Est. Completion | 2019-01-10 |
| Phase | Phase 1 |
Why NCT03166800 stopped before completion
NCT03166800 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03166800 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03166800 about?
NCT03166800 is a clinical study titled "MitoQ for Fatigue in Multiple Sclerosis". The purpose of this study is to determine whether MS patients who receive Oral mitoquinone (MitoQ) have less fatigue than those receiving a placebo. A comparison between patient's fatigue scored at baseline and fatigue scored 12 weeks after study drug initiation will assess if MitoQ has a significan...
What is the current status of trial NCT03166800?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2018-09-15. Estimated completion is 2019-01-10.
What interventions are being tested in trial NCT03166800?
The interventions under investigation include: Placebo (DRUG), Mitoquinone (DRUG).
Who is sponsoring clinical trial NCT03166800?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03166800's enrollment target sits among peer trials
9 1955th of 2000 higher than 42 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI